As previously reported, Wells Fargo upgraded Medtronic to Overweight from Equal Weight with a price target of $100, up from $77. The firm thinks Medtronic will benefit from an improvement in the underlying medtech markets. Furthermore, Wells Fargo believes the pipeline is improving and that valuation appears attractive.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MDT:
- Medtronic Gains Ground Following Analyst Praise
- Medtronic upgraded to Overweight from Equal Weight at Wells Fargo
- Medtronic announces FDA approval of MiniMed 780G system
- Tandem Diabetes down 5% after FDA approves Medtronic’s MiniMed 780G
- Medtronic up 3% after FDA approves expanded indication for MiniMed 780G System
